Valued at a market cap of $18.2 billion, Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the ...

The global personal genome testing market is on a remarkable growth trajectory, projected to soar to USD 4,468 million by 2032, up from USD 1,545.5 million in 2022. This growth reflects a robust CAGR ...

Redburn Atlantic began coverage on shares of Quest Diagnostics (NYSE:DGX – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $195.00 price ...

Shares of Quest Diagnostics Inc. DGX slid 3.78% to $164.18 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074.08 ...

Workers at Lifelabs on Victoria St. are now part of a province-wide strike against their American employer, Quest Diagnostics ...

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

PRINCE GEORGE – As part of a series of rotating strikes across the province, LifeLabs workers in Prince George went on strike ...

REGINA — Saskatchewan's health minister says he can't pull the plug on a contract with an American company offering lab ...

Fintel reports that on April 2, 2025, Redburn Atlantic initiated coverage of Quest Diagnostics (NYSE:DGX) with a Buy recommendation. Analyst Price Forecast Suggests 7.56% Upside As of March 19, 2025, ...

Redburn Atlantic analyst Jamie Clark initiated coverage of Quest Diagnostics (DGX) with a Buy rating and $195 price target Don't Miss Our End ...

This was the stock's second consecutive day of gains.

The most recent lawsuit is from winter 2024, when the California attorney general announced a $5 million settlement with ...